With its acquisition of Ireland's Amryt Pharma set to complete shortly after Easter, Chiesi Farmaceutici S.p.A. can expect a healthy rise in revenues for 2023 having just posted a strong set of financials for last year.
The Italian drugmaker recorded turnover of €2.75bn in 2022, an increase of 13.6% on the previous year, while its cash...








